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Practice guideline: Cervical and ocular
vestibular evokedmyogenic potential testing
Report of the Guideline Development, Dissemination, and
Implementation Subcommittee of the American Academy of Neurology
ABSTRACT
Objective: To systematically review the evidence and make recommendations with regard to diag-
nostic utility of cervical and ocular vestibular evoked myogenic potentials (cVEMP and oVEMP,
respectively). Four questions were asked: Does cVEMP accurately identify superior canal dehis-
cence syndrome (SCDS)? Does oVEMP accurately identify SCDS? For suspected vestibular
symptoms, does cVEMP/oVEMP accurately identify vestibular dysfunction related to the sac-
cule/utricle? For vestibular symptoms, does cVEMP/oVEMP accurately and substantively aid
diagnosis of any specific vestibular disorder besides SCDS?
Methods: The guideline panel identified and classified relevant published studies (January 1980–
December 2016) according to the 2004 American Academy of Neurology process.
Results and Recommendations: Level C positive: Clinicians may use cVEMP stimulus threshold
values to distinguish SCDS from controls (2 Class III studies) (sensitivity 86%–91%, specificity
90%–96%). Corrected cVEMP amplitude may be used to distinguish SCDS from controls (2
Class III studies) (sensitivity 100%, specificity 93%). Clinicians may use oVEMP amplitude to
distinguish SCDS from normal controls (3 Class III studies) (sensitivity 77%–100%, specificity
98%–100%). oVEMP threshold may be used to aid in distinguishing SCDS from controls (3 Class
III studies) (sensitivity 70%–100%, specificity 77%–100%). Level U: Evidence is insufficient to
determine whether cVEMP and oVEMP can accurately identify vestibular function specifically
related to the saccule/utricle, or whether cVEMP or oVEMP is useful in diagnosing vestibular
neuritis or Ménière disease. Level C negative: It has not been demonstrated that cVEMP sub-
stantively aids in diagnosing benign paroxysmal positional vertigo, or that cVEMP or oVEMP aids
in diagnosing/managing vestibular migraine. Neurology® 2017;89:2288–2296
GLOSSARY
AAN 5 American Academy of Neurology; BPPV 5 benign paroxysmal positional vertigo; CI 5 confidence interval; cVEMP 5
cervical vestibular evoked myogenic potential; nHL 5 normal hearing level; oVEMP 5 ocular vestibular evoked myogenic
potential; SCDS 5 superior canal dehiscence syndrome; VEMP 5 vestibular evoked myogenic potential; VM 5 vestibular
migraine; VN 5 vestibular neuritis.
Vestibular evoked myogenic potential (VEMP) test-
ing averages short latency myogenic responses evoked
by sound that stimulates activation of the saccule or
utricle, or both.1,2 The US Food and Drug Adminis-
tration approved VEMP in October 2015. Caloric
testing assesses only horizontal semicircular canal
vestibulo-ocular reflex function, and the video head
impulse test assesses function of all 6 semicircular
canals, whereas VEMP testing appears to assess func-
tion of only the saccule/utricle.3–6
Types of VEMP testing. There are 2 types of VEMP
testing: cervical VEMP (cVEMP) and ocular VEMP
(oVEMP).
The cVEMP test is believed to assess saccular ves-
tibular signals carried via the vestibulospinal tract.7
cVEMP is performed by applying sound stimulation
to 1 ear while recording surface EMG over the ipsi-
lateral sternocleidomastoid muscle (figure 1). Sound-
responsive vestibular cells, mainly within the inner ear
saccule, momentarily inhibit ipsilateral muscle tone
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via the cervical vestibulocollic pathway (figure 2).8–10
Surface EMG responses from the tonically contracted
ipsilateral sternocleidomastoid muscle are averaged to
yield a biphasic waveform response (figure 3).
cVEMP responses can also be derived from the mas-
seter, triceps, and gastrocnemius muscles.11,12
The oVEMP test is believed to measure vestibular
function from the utricle via the superior vestibular
nerve, which then crosses the midline to the contra-
lateral medial longitudinal fasciculus and the oculo-
motor nucleus (figure 4).9,13 oVEMP does not
substantially involve the semicircular canals.14
oVEMP uses an air- or bone-conducted sound stim-
ulus and averages the surface EMG responses from
the contralateral inferior oblique muscle (figure 4) to
yield a biphasic waveform (figure 5). Measurements
are made of the latencies of the early peaks (n10 or n1
and p16 or p2 for oVEMP) and a peak-to-peak
amplitude (figure 5).
Technical considerations in VEMP. cVEMP technical
standards have been proposed.15 VEMP responses
attenuate after age 60 years, and thus the studies
included here apply to people aged ,60 years.16,17
Sensorineural hearing loss does not affect cVEMP/
oVEMP.18 Conductive hearing loss may reduce
sound intensity at the oval window and render
VEMP responses unobtainable. For both cVEMP
and oVEMP, the minimum sound stimulus needed
to evoke a biphasic VEMP response is called the
threshold (table e-1 at Neurology.org).
This guideline addresses published evidence
related to cVEMP and oVEMP for peripheral vestib-
ular disorders.
Superior canal dehiscence syndrome. Superior canal
dehiscence syndrome (SCDS) is caused by an abnor-
mal opening (dehiscence) in the temporal bone that
forms the roof of the superior semicircular canal.19
Overall, 1%–2% of the population has abnormal
thinning of the temporal bone near the superior semi-
circular canal.20 Further erosion may occur with age.21
The average age at diagnosis is 46 years.22 Dehiscence
renders the membranous labyrinth unusually suscep-
tible to sound and pressure changes.
SCDS diagnosis is based on the combination of
vestibular and auditory signs and symptoms and tem-
poral bone CT. Patients with SCDS commonly
report pressure-induced (coughing, sneezing, strain-
ing) and sound-induced vertigo, dizziness, and the
Tullio phenomenon (dizziness induced by sound)
or autophony (hearing one’s internal body sounds)
due to increased sensitivity to sound conducted
through bone. Clinical examination may reveal eye
movements induced by Valsalva maneuvers, by pres-
sure in the external auditory canal, or by sounds.19,23
Patients may have an air–bone gap, especially at the
lower frequencies.24 For those with disabling symp-
toms, case series suggest a benefit with surgical plug-
ging or resurfacing of the bony opening.25
A 2000 American Academy of Neurology (AAN)
guideline provides guidance on vestibular testing
techniques in adults and children.26 In this new
guideline, 4 questions were asked regarding the diag-
nostic accuracy of cVEMP and oVEMP: (1) Does
cVEMP accurately identify SCDS? (2) Does oVEMP
accurately identify SCDS? (3) For suspected vestibu-
lar symptoms, does cVEMP/oVEMP accurately iden-
tify vestibular dysfunction related to the saccule/
utricle? (4) For vestibular symptoms, does cVEMP/
oVEMP accurately and substantively aid in diagnosis
of any specific vestibular disorder besides SCDS?
DESCRIPTION OF THE ANALYTIC PROCESS In
September 2010, the AAN guideline subcommittee
convened an expert panel to develop this practice
guideline (appendices e-1 and e-2), following the pro-
cess described in the 2004 AAN process manual.27
The panel searched MEDLINE, Cochrane Central
Register of Controlled Trials (CENTRAL), Literatura
Latino Americana em Ciências da Saúde (LILACS),
and Science Citation Index for relevant articles in all
languages published from January 1, 1980, through
March 1, 2015, finding only relevant articles in
Figure 1 Electrode placement montage for
cervical vestibular evoked myogenic
potential of the right ear
Surface recording electrodes are placed on the tonically
contracted right sternocleidomastoid (achieved by having
the patient actively turn the head to the left and lift the head
slightly) during recordings. © Barrow Neurological Institute,
Phoenix, AZ. Used with permission.
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English. A search update (November 2016) sought
articles published March 1, 2015, through November
1, 2016. Included studies examined utility of VEMP
in diagnosis, including case control, cohort, case series
(n . 6), or meta-analyses. Studies were excluded if
they were not relevant to VEMP or vestibular dis-
orders, or were not peer reviewed. Key words were
“click evoked myogenic,” “vestibular evoked myo-
genic,” and “VEMP.”
The search yielded 2,536 articles, whose titles and
abstracts were reviewed for relevance by at least 2
panel members. Of those articles, 257 underwent
full-text review for inclusion by at least 2 panelists
(including an AAN evidence-based medicine meth-
odologist), who identified 97 articles as relevant and
rated them according to the 2004 AAN diagnostic
accuracy scheme for classification of risk of bias
(appendix e-3). A third panelist adjudicated disagree-
ments in ratings. The panel then narrowed the guide-
line focus to exclude VEMP use in disorders affecting
vestibulospinal spinal cord conduction, and thus dis-
carded 39 articles on this topic, leaving 58 remaining
articles that were rated. Because no articles attained
a Class I or II rating, only Class III studies were
included. Recommendation levels were tied directly
to the evidence (appendix e-4). Tables e-2 through
e-4 describe how vestibular diagnoses were deter-
mined in the rated articles.
ANALYSIS OF EVIDENCE Does cVEMP accurately
identify patients with SCDS? There were 9 Class III
studies.24,25,28–34 A meta-analysis was considered but
not performed given the heterogeneity of the studies.
cVEMP threshold. There were 2 positive Class III
studies24,25 and another Class III study downgraded
for the question of threshold due to incorporation
bias.28
The first study was a retrospective cohort of 65
patients.24 At the 500-Hz tone bursts, VEMP
thresholds were 66 dB (95% confidence interval
[CI] 62.1–67.0 dB) for SCDS ears and 85 dB
(95% CI 82.6–87.4 dB) for non-SCDS ears. The
cVEMP using a threshold of #65 dB normal hear-
ing level (nHL) yielded 91.4% sensitivity and
95.8% specificity.
The second study (case control) examined the
cVEMP threshold values of 29 patients with sus-
pected SCDS and 50 healthy control ears.25 The best
combination of sensitivity and specificity was found
using cVEMP threshold of #85 dB nHL, which
yielded 86% sensitivity (95% CI 66%–95%) and
90% specificity (95% CI 77%–96%) in separating
patients with SCDS from controls.
cVEMP amplitude. Two negative underpowered
Class III studies30,31 showed that cVEMP raw ampli-
tude possibly did not effectively detect SCDS.
The first study of 67 patients compared 17 CT-
demonstrated SCDS ears with 107 CT-
demonstrated non-SCDS ears.30 After a Bonferroni
correction, no significant differences were found.
The second study used a striker to enhance
cVEMP responses and included 5 patients with
SCDS and 20 normal controls.31 The mean ampli-
tudes were 53.3 mV (95% CI 29.9–76.8 mV) for
controls and 63.1 mV (95% CI 52.0–74.4 mV) for
those with SCDS, but there was too much overlap to
separate SCDS ears from controls.
Corrected cVEMP amplitude. There were 5 Class III
studies that addressed corrected VEMP ampli-
tudes.28,29,32–34 For air-conducted cVEMP ampli-
tudes, lower stimulus intensity may be more effective
Figure 2 The predominant reflex pathway mediating cervical vestibular evoked
myogenic potential responses
Sound stimulates the saccule, which carries the signal through the ipsilateral inferior vestib-
ular nerve to the vestibular nucleus from which vestibulospinal (vestibulocollic) pathway
transmits a momentary inhibitory signal to the spinal accessory nerve supplying the ipsilat-
eral sternocleidomastoid muscle. The momentary inhibitory responses are averaged as
evoked potentials. I 5 inferior vestibular nucleus; L 5 lateral vestibular nucleus; M 5 medial
vestibular nucleus; S 5 superior vestibular nucleus; VI 5 abducens nucleus. © Barrow
Neurological Institute, Phoenix, AZ. Used with permission.
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at distinguishing SCDS from normal because of sat-
uration at greater stimulus intensities.28,32
The first study examined 20 healthy controls vs
SCDS ears in 10 affected patients33 and found the
VEMP-corrected amplitude of SCDS-affected ears,
2.78 (95% CI 2.69–2.87), was significantly greater
than in controls, 1.29 (95% CI 1.22–1.37). The
study also found surgical repair of the dehiscence with
canal plugging resulted in normalization of corrected
cVEMP amplitudes.
The second study reported a mean corrected
amplitude of 0.23 6 0.28 (95% CI 0.18–0.28) for
113 controls and 1.75 6 0.61 (95% CI 1.50–2.01)
for 22 SCDS ears.32 With use of a corrected cVEMP
amplitude of 0.8 (determined from normal mean
0.23 1 2 SD), cVEMP amplitude had a sensitivity
of 100% (22/22) and specificity of 93% (115/113).
In the third study, patients with SCDS had a sig-
nificantly larger mean corrected amplitude, 3.0 (95%
CI 2.41–3.56), than controls, 1.25 (95% CI 1.05–
1.45).34 Of patients and controls aged .40 years,
93.8% had corrected amplitude values greater than
the mean 12 SD of the control group. However,
neither the sensitivity nor the specificity could be
determined in this subset.
The fourth study (underpowered) compared 11
patients who had SCDS with 11 controls.29 The
mean difference between the corrected peak-to-peak
amplitudes for patients with SCDS and controls was
not significant for click stimulus, 2.2 (95% CI 0.1–
4.3), or tone burst stimulus, 3.5 (95% CI 0–7.1).
The final study compared 13 patients who had
known SCDS with 15 normal controls.28 With use
of a stimulus intensity of 105 dB pSPL and a corrected
amplitude cutoff of 2.5 SD above the controls mean,
cVEMP had a sensitivity of 100% (13/13) and spec-
ificity of 93% (14/15) in distinguishing patients with
SCDS from controls.
Conclusions. cVEMP threshold values possibly dis-
tinguish patients with SCDS from controls (2 Class
III studies) with sensitivity of 86%–91% and speci-
ficity of 90%–96%. Corrected cVEMP amplitude
possibly distinguishes patients with SCDS from con-
trols (2 Class III and 3 underpowered Class III stud-
ies) with sensitivity of 100% and specificity of 93%.
Raw cVEMP amplitude values possibly do not dis-
tinguish patients with SCDS from controls (2 under-
powered Class III studies).
Recommendations. Clinicians may use cVEMP
threshold values to distinguish patients with SCDS
from controls (Level C). Corrected cVEMP ampli-
tude may also be used to distinguish patients with
SCDS from controls (Level C).
Does oVEMP accurately identify patients with SCDS?
Seven Class III studies were identified.25,28,29,31,35–37
oVEMP amplitude. One retrospective study looked
at 9 patients with SCDS matched to controls.35 Mean
raw amplitudes were greater in SCDS ears, 2.68 mV
(95% CI 2.46–2.90 mV), than in controls, 0.93 mV
(95% CI 0.91–0.95 mV). Using an n10 amplitude of
$1.5 mV, oVEMP had 100% sensitivity and 100%
specificity in differentiating patients with SCDS from
controls.
A second study28 compared SCDS ears with nor-
mal ears. The mean amplitude of patients with SCDS
was significantly higher, 35.9mV (95%CI 26.7–45.1
mV), than controls, 8.9 mV (95% CI 6.24–11.56
mV). With use of a stimulus intensity of 105 dB pSPL
and corrected amplitude of.2.5 SD above the mean
of normal controls, oVEMP amplitudes had a 77%
(10/13) sensitivity and 100% (15/15) specificity in
distinguishing SCDS ears from normal ears.
A third study examined the oVEMP n10 ampli-
tude of 29 ears in patients with suspected SCDS com-
pared with 50 control ears.25 Use of an n10 amplitude
of $9.3 mV as the cutoff yielded a sensitivity of
100% (95% CI 88%–100%) and specificity of
100% (95% CI 93%–100%). Using an oVEMP
peak-to-peak amplitude of .17.1 mV as the cutoff
resulted in 100% sensitivity (95% CI 85%–100%)
and 98% specificity (95% CI 89%–100%).
A fourth study, described previously, compared
oVEMP n10 amplitudes using 4 different stimuli.29
Use of an n10 amplitude of $8.25 mV as the cutoff
yielded a sensitivity of 100% (95% CI 72%–100%)
and a specificity of 100% (95% CI 72%–100%).
In a fifth study comparing SCDS ears with normal
ears,31 controls had a mean of 12.31 mV (95% CI
10.9–13.7 mV). SCDS-affected ears had a mean of
Figure 3 Cervical vestibular evoked myogenic potential (cVEMP) waveform in
a healthy individual
The recordings are from the right sternocleidomastoid muscle in response to 500-Hz tone
bursts (2 ms duration, 2 ms rise/fall), with an intensity of 130 dB pSPL. The waveform shows
the positive–negative cVEMP (p13-n23) on the side to which the sound stimulation is
applied. Measurements include the latency, the amplitude, and the threshold (least intense
sound stimulus to still yield a reliable response). The responses occur only on the side of the
sound stimulation. Some laboratories display an inverted waveform with the positive wave
up instead of the negative wave up. © Barrow Neurological Institute, Phoenix, AZ. Used with
permission.
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12.14 mV, but no information was given about SDs,
and sensitivity and specificity could not be
determined.
oVEMP evoked by stimulus 4,000-Hz tone burst at the
midline forehead. One study, aiming to find a single
method to distinguish SCDS ears from normal ears,
compared 30 SCDS ears with 44 control ears36 after
application of a 4,000-Hz sound stimulus to the mid-
line forehead. All SCDS ears had an oVEMP response,
and none of the 44 healthy ears had an oVEMP response,
yielding 100% sensitivity and 100% specificity.
oVEMP threshold. Two studies supported use of
oVEMP stimulus threshold.28,37
The first study, comparing 10 SCDS ears with
those of 10 normal controls, found that the mean
threshold in patients with SCDS was 101.2 6
5.5 dB pSPL compared with 116.7 6 4.7 dB pSPL
for controls (p , 0.001), and all patients with SCDS
had abnormally low threshold values.37
The second study, described earlier, found that
using an oVEMP stimulus threshold value ,105 dB
pSPL achieved a sensitivity of 100% (13/13) and spec-
ificity of 92% (14/15). When a threshold of ,99 dB
pSPL as abnormal was applied, patients with SCDS
were differentiated from controls with sensitivity of
76.9% (10/13) and specificity of 93.3% (14/15).28
Conclusions. oVEMP amplitude possibly distin-
guishes SCDS from normal controls (3 Class III, 2
underpowered or inconclusive studies) with a sensitiv-
ity range of 77%–100% and a specificity range of
98%–100%. The efficacy is unknown for use of
a 4,000-Hz stimulus to determine the presence or
absence of an oVEMP response to differentiate ears
with SCDS from normal ears (1 positive Class III
study). An oVEMP threshold below a laboratory-
specific value (usually 2 SD below the mean thresh-
old of controls) possibly distinguishes SCDS ears
from normal ears with a sensitivity of 77% and
a specificity of 93% (2 Class III studies).
Recommendation. oVEMP testing using either spe-
cific thresholds or amplitudes may be used in patients
to aid in making an SCDS diagnosis (Level C).
Figure 4 The predominant reflex pathway mediating ocular vestibular evoked myogenic potential responses
Sound stimulates the utricle, which carries the signal through the ipsilateral superior vestibular nerve to the ipsilateral ves-
tibular nucleus. The utriculo-ocular signals cross themidline and travel up the medial longitudinal fasciculus to send an excit-
atory stimulus to the inferior oblique subnucleus of the oculomotor nucleus, causing momentary contraction which is
averaged repetitively. I 5 inferior vestibular nucleus; III 5 oculomotor nucleus; L 5 lateral vestibular nucleus; M 5 medial
vestibular nucleus; MLF 5 medial longitudinal fasciculus; S 5 superior vestibular nucleus; VI 5 abducens nucleus; VN 5
vestibular nucleus. © Barrow Neurological Institute, Phoenix, AZ. Used with permission.
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Clinical context for VEMP testing for SCDS. Both
cVEMP and oVEMP in SCDS may show an abnor-
mal response that is actually hyperactive. That is,
SCDS requires a less intense sound stimulus than
normal (i.e., lower threshold) to induce the response,
and the response amplitude is abnormally increased
on the affected side. No other vestibular disorder
has yet demonstrated hyperactive VEMP responses
to such a degree.
The false appearance of dehiscence by CT of the
temporal bone can sometimes be seen in patients
without SCDS.38–40 In some cases, a negative CT of
the temporal bone but abnormal VEMP is due to
dehiscence in a canal other than the superior
canal.24,e1 To confirm SCDS, cVEMP and oVEMP
provide a physiologic correlate to the clinical symp-
toms and the temporal bone CT findings. Hence,
VEMP studies serve a complementary role in con-
junction with temporal bone CT and clinical history
in SCDS diagnosis. Normalization of VEMP ampli-
tudes and thresholds after successful surgical repair of
SCDS is further confirmation that VEMP studies
correlate with the presence of a physiologically signif-
icant degree of dehiscence.33
For patients with suspected vestibular symptoms, does
cVEMP/oVEMP accurately identify vestibular dysfunc-
tion related to the saccule/utricle? Because there is no
reference standard test for isolated saccular/utricular
loss, no method exists to directly determine in hu-
mans whether cVEMP responses reflect saccular
function and whether oVEMP responses reflect utric-
ular function. The guideline authors found studies
correlating caloric vestibular loss with absence of
oVEMP responses in vestibular neuritis (VN), but
this only implies the relationship. Ultimately, this
question was unanswerable using AAN guideline
methodology.
Clinical context for cVEMP as a measure of saccular
dysfunction and oVEMP as a measure of utricular
dysfunction. Historically, animal studies have been
essential in understanding the vestibular system.e2 For
example, animal studies were a critical part of deter-
mining that caloric testing is a measure of horizontal
semicircular canal function, which is now accepted.6,e3
In the case of VEMP, animal studies suggest that
cVEMP is most closely tied to function of the saccule
and oVEMP to the utricle, although with some possi-
ble contribution from the semicircular canals.9,26,28,e4,e5
Conclusion. It is not known whether oVEMP/
cVEMP responses accurately identify vestibular func-
tion specifically related to the saccule/utricle (no rel-
evant studies).
Recommendation. cVEMP and oVEMP have
unknown efficacy in accurately identifying vestibular
function specifically related to the saccule/utricle
(Level U).
For patients with vestibular symptoms, does cVEMP/
oVEMP accurately and substantively aid diagnosis of any
specific vestibular disorder besides SCDS? Vestibular
neuritis. Class III studies have applied VEMP to VN.
VEMP is viewed as helpful in identifying whether
VN has led to dysfunction related to the superior or
inferior (or both) branches of the vestibular
nerve,e6–e9 supporting rather thanmaking the diagnosis.
Clinical context. VN remains a clinical diagnosis with
symptoms of acute vestibular dysfunction, normal
hearing, and typical signs.e10 Use of VEMP to parse
out which parts of the nerve or labyrinth are affected
is predicated on the notion that cVEMP is indicative
of saccular function and oVEMP of utricular func-
tion. Although this notion is biologically plausible
and supported by animal studies, and studies of VN
have found that caloric loss correlates strongly with
absence of oVEMP responses, direct evidence in hu-
mans of the type acceptable within the AAN guide-
line process is currently absent.
Conclusion. Expert consensus supports use of
cVEMP and oVEMP to determine the extent of
VN involvement, but with the methods used herein,
no such determination can be made.
Recommendation. Evidence is insufficient to deter-
mine whether cVEMP/oVEMP use would clarify
which vestibular structures are affected in VN
(Level U).
Ménière disease. All 8 studies on Ménière disease are
Class III,e11–e18 most of which were downgraded
because of spectrum bias.
One study examined the ratio of oVEMP ampli-
tudes at 500-Hz and 750-Hz sound stimulus.e11
Figure 5 Ocular vestibular evoked myogenic potential (oVEMP) waveform in
a healthy individual
The recordings are from the surface EMG electrodes over the left inferior oblique in
response to a sound stimulus in the right ear. The waveform shows the negative–positive
oVEMP (n10-p16, sometimes simply referred to as n1 and p1). Measurements include the
latency, the amplitude, and the threshold (least intense sound stimulus to still yield a reliable
response). The responses occur only on the side opposite the one receiving the sound
stimulation. © Barrow Neurological Institute, Phoenix, AZ. Used with permission.
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Comparing the amplitude ratio of 750 Hz to 500 Hz
with cutoff of.1.21 yielded a sensitivity of 89% and
a specificity of 100% when patients with Ménière
disease were compared with controls.
Another studye7 showed no distinction of Ménière
disease from controls for cVEMP/oVEMP.
Other Class III studies also examined cVEMP in
Ménière disease.e13–e18 None demonstrated an ability
as a stand-alone diagnostic test to reliably diagnose
Ménière disease. Some showed vestibular dysfunction
manifesting as an ipsilaterally absent response.
Conclusion. On the basis of multiple conflicting or
inconclusive studies, neither cVEMP nor oVEMP
testing was found to be useful in diagnosing Ménière
disease, but the studies possibly demonstrate that ves-
tibular loss as assessed by VEMP may be seen in
Ménière disease.
Recommendations. cVEMP may be used as an ancil-
lary test in Ménière disease for vestibular dysfunction
(Level C). There is insufficient evidence that either
cVEMP or oVEMP may be used to diagnose Ménière
disease (Level U).
Clinical context for using VEMP in Ménière disease. The
diagnosis of Ménière disease has long been a clinical
one,e19 and only recently has audiometry been added
to the diagnostic criteria.e20 There is no demonstrable
role of VEMP in diagnosis of Ménière disease.
Benign paroxysmal positional vertigo. Two Class III
studiese21,e22 examined cVEMP responses in patients
with benign paroxysmal positional vertigo (BPPV)
compared with those of healthy controls. Neither
study found cVEMP to aid in establishing the BPPV
diagnosis or to reliably distinguish patients with
BPPV from controls.
Conclusion. cVEMP was not demonstrated to aid in
establishing BPPV diagnosis (2 Class III studies).
Recommendation. cVEMP may not be used to make
a BPPV diagnosis (Level C).
Clinical context for use of VEMP to diagnose BPPV.Diagnos-
tic criteria for BPPV have been published.e23 No role
for VEMP in the diagnosis of BPPV has been
established.
Vestibular migraine. Three Class III studies ad-
dressed vestibular migraine (VM).e18,e24,e25
The first study found absence of a cVEMP
response in one or both ears in 44% (16/37) of pa-
tients with VM and in 3% (1/30) of controls, yielding
a sensitivity of 43% (95% CI 27.5%–60.3%) and
a specificity of 97% (95% CI 80.9%–99.8%).e24
The second study used cVEMP measurements
and found a sensitivity of 31% using absence of
a response as an indicator of VM.e18 This lack of
response, however, is not diagnostic of VM, and
the study authors made no assertion that cVEMP
is helpful in distinguishing patients with VM from
controls.
The third study found more absent oVEMP or
asymmetric oVEMP amplitude responses in 39 pa-
tients with VM than in 29 controls; however,
cVEMP responses were not statistically different
between the 2 groups.e25
Conclusion. In patients with VM, it is possible an
absent VEMP response or asymmetric amplitude is
more common than in controls, but in no study
was VEMP useful in establishing a VM diagnosis.
Recommendation. Although an absent VEMP
response in one or both ears appears to occur more
often in patients with VM than in normal controls,
VEMP may not be used to assist in VM diagnosis
or management (Level C).
Clinical context for using VEMP in VM. VM is a clinical
diagnosis with established clinical criteria.e26 No ves-
tibular test makes the diagnosis of VM, but vestibular
tests, including VEMP, may clarify the status of ves-
tibular function when needed to exclude other
conditions.
Other vestibular conditions. The guideline panel
found insufficient data to determine the usefulness
of VEMP in diagnosing other vestibular disorders.
Conclusion/recommendation. Data are insufficient to
make recommendations regarding use of VEMP in
diagnosis of other specific vestibular disorders besides
SCDS (Level U).
RECOMMENDATIONS FOR FUTURE RESEARCH
More standardization is needed of stimulation and
recording methods, and of normal and pathologic
ranges of the amplitudes and latencies, with specifica-
tions of the reporting measures, if cVEMP and
oVEMP are to be used more effectively in clinical
practice.16,e27 This also requires that each laboratory
determine its own normal and pathologic ranges for
each test for younger and older patients. Quality stud-
ies with low risk of bias are needed to better inform
the role of VEMP in clinical evaluation of various
otologic and neurologic disorders. Human studies
are needed to confirm that cVEMP and oVEMP
are indicative predominantly of saccular and utricular
function, respectively.
DISCLAIMER Clinical practice guidelines, practice
advisories, systematic reviews, and other guidance
published by the American Academy of Neurology
and its affiliates are assessments of current scientific
and clinical information provided as an educational
service. The information (1) should not be considered
inclusive of all proper treatments, methods of care, or
as a statement of the standard of care; (2) is not
continually updated and may not reflect the most
recent evidence (new evidence may emerge between
the time information is developed and when it is
published or read); (3) addresses only the question(s)
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specifically identified; (4) does not mandate any
particular course of medical care; and (5) is not in-
tended to substitute for the independent professional
judgment of the treating provider, as the information
does not account for individual variation among pa-
tients. In all cases, the selected course of action should
be considered by the treating provider in the context
of treating the individual patient. Use of the infor-
mation is voluntary. AAN provides this information
on an “as is” basis, and makes no warranty, expressed
or implied, regarding the information. AAN specifi-
cally disclaims any warranties of merchantability or
fitness for a particular use or purpose. AAN assumes
no responsibility for any injury or damage to persons
or property arising out of or related to any use of this
information or for any errors or omissions.
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